CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that the company will be presenting at BIO InvestorForum 2007, which is being held from October 9-11, 2007 at the Palace Hotel in San Francisco.
Daniel Passeri, Curis' President and Chief Executive Officer, will conduct a presentation in the Telegraph Room at the Palace Hotel at 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) on October 10, 2007. Mr. Passeri's presentation will provide an overview of the status of Curis' business, including CUDC-101 and the other proprietary small molecule cancer programs under Curis' Targeted Cancer Drug Development Platform. There will also be a corresponding webcast of the presentation, which can be accessed by visiting: www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CRIS&item_id=1657582
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com
SOURCE: Curis, Inc.